scholarly journals Albumin-Albumin/Lactosylated Core-Shell Nanoparticles: Therapy to Treat Hepatocellular Carcinoma for Controlled Delivery of Doxorubicin

Molecules ◽  
2020 ◽  
Vol 25 (22) ◽  
pp. 5432
Author(s):  
Nayelli Guadalupe Teran-Saavedra ◽  
Jose Andrei Sarabia-Sainz ◽  
Enrique Fernando Velázquez-Contreras ◽  
Gabriela Ramos-Clamont Montfort ◽  
Martín Pedroza-Montero ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Side Effects ◽  
Hepg2 Cells ◽  
Core Shell ◽  
Shell Nanoparticles ◽  
Human Liver Cancer ◽  
Systemic Side Effects ◽  
Human Liver Cancer Cells ◽  
Core Shell Nanoparticles

Doxorubicin (Dox) is the most widely used chemotherapeutic agent and is considered a highly powerful and broad-spectrum for cancer treatment. However, its application is compromised by the cumulative side effect of dose-dependent cardiotoxicity. Because of this, targeted drug delivery systems (DDS) are currently being explored in an attempt to reduce Dox systemic side-effects. In this study, DDS targeting hepatocellular carcinoma (HCC) has been designed, specifically to the asialoglycoprotein receptor (ASGPR). Dox-loaded albumin-albumin/lactosylated (core-shell) nanoparticles (tBSA/BSALac NPs) with low (LC) and high (HC) crosslink using glutaraldehyde were synthesized. Nanoparticles presented spherical shapes with a size distribution of 257 ± 14 nm and 254 ± 14 nm, as well as an estimated surface charge of −28.0 ± 0.1 mV and −26.0 ± 0.2 mV, respectively. The encapsulation efficiency of Dox for the two types of nanoparticles was higher than 80%. The in vitro drug release results showed a sustained and controlled release profile. Additionally, the nanoparticles were revealed to be biocompatible with red blood cells (RBCs) and human liver cancer cells (HepG2 cells). In cytotoxicity assays, Dox-loaded nanoparticles decrease cell viability more efficiently than free Dox. Specific biorecognition assays confirmed the interaction between nanoparticles and HepG2 cells, especially with ASGPRs. Both types of nanoparticles may be possible DDS specifically targeting HCC, thus reducing side effects, mainly cardiotoxicity. Therefore, improving the quality of life from patients during chemotherapy.

Combination of Zizyphus jujuba and Green Tea Extracts Exerts Excellent Cytotoxic Activity in HepG2 Cells via Reducing the Expression of APRIL

2009 ◽  
Vol 37 (01) ◽  
pp. 169-179 ◽  
Author(s):  
Xuedan Huang ◽  
Akiko Kojima-Yuasa ◽  
Shenghui Xu ◽  
David Opare Kennedy ◽  
Tadayoshi Hasuma ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Anticancer Activity ◽  
Green Tea ◽  
Hepg2 Cells ◽  
Chemotherapeutic Agents ◽  
Chloroform Fraction ◽  
The Future ◽  
Human Liver Cancer ◽  
Human Liver Cancer Cells

Hepatocellular carcinoma is a type of tumor highly resistant to available chemotherapeutic agents. The treatment of hepatocellular carcinoma remains a challenge that needs new approaches in the future. In a previous study, we demonstrated that the chloroform fraction (CHCl3-F) from Z. jujuba has anticancer activity in human liver cancer cells (HepG2), and that combining CHCl3-F with green tea extracts (GTE) results in enhanced effects of anticancer activity in the cells. To further understand the mechanism of the anticancer activity of combining CHCl3-F and GTE in HepG2 cells, we investigated whether the addition of a mixture of CHCl3-F and GTE would affect the expression of APRIL (a proliferation-inducing ligand), which was expressed in HepG2 cells from 4 hours of incubation in vitro. We have shown that CHCl3-F and GTE enhanced anti-cancer activity by reducing the expression of APRIL. We speculate that the CHCl3-F and GTE mixture might provide a lead to a new drug design to treat hepatocellular carcinoma in the future.

PEG-Iron Oxide Core-Shell Nanoparticles: In situ Synthesis and In vitro Biocompatibility Evaluation for Potential T2-MRI Applications

2020 ◽  
Vol 10 (4) ◽  
pp. 1107-1120
Author(s):  
Karina Almeida Barcelos ◽  
Marli Luiza Tebaldi ◽  
Eryvaldo Socrates Tabosa do Egito ◽  
Nádia Miriceia Leão ◽  
Daniel Cristian Ferreira Soares
Keyword(s):  
Iron Oxide ◽  
In Situ Synthesis ◽  
Core Shell ◽  
Shell Nanoparticles ◽  
In Vitro Biocompatibility ◽  
Iron Oxide Core ◽  
Core Shell Nanoparticles ◽  
T2 Mri

scholarly journals Houttuynia cordata Thunb Promotes Activation of HIF-1A–FOXO3 and MEF2A Pathways to Induce Apoptosis in Human HepG2 Hepatocellular Carcinoma Cells

2016 ◽  
Vol 16 (3) ◽  
pp. 360-372 ◽  
Author(s):  
Jung Min Kim ◽  
In-Hu Hwang ◽  
Ik-Soon Jang ◽  
Min Kim ◽  
In Seok Bang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepg2 Cells ◽  
Target Genes ◽  
Hypoxia Inducible Factor ◽  
Carcinoma Cells ◽  
Houttuynia Cordata ◽  
Hepatocellular Carcinoma Cells ◽  
Human Liver Cancer ◽  
Houttuynia Cordata Thunb ◽  
Human Liver Cancer Cells

Houttuynia cordata Thunb ( H cordata), a medicinal plant, has anticancer activity, as it inhibits cell growth and induces cell apoptosis in cancer. However, the potential anti-cancer activity and mechanism of H cordata for human liver cancer cells is not well understood. Recently, we identified hypoxia-inducible factor (HIF)-1A, Forkhead box (FOX)O3, and MEF2A as proapoptotic factors induced by H cordata, suggesting that HIF-1A, FOXO3, and MEF2A contribute to the apoptosis of HepG2 hepatocellular carcinoma cells. FOXO3 transcription factors regulate target genes involved in apoptosis. H cordata significantly increased the mRNA and protein expression of HIF-1A and FOXO3 and stimulated MEF2A expression in addition to increased apoptosis in HepG2 cells within 24 hours. Therefore, we determined the potential role of FOXO3 on apoptosis and on H cordata–induced MEF2A in HepG2 cells. HIF-1A silencing by siRNA attenuated MEF2A and H cordata–mediated FOXO3 upregulation in HepG2 cells. Furthermore, H cordata–mediated MEF2A expression enhanced caspase-3 and caspase-7, which were abolished on silencing FOXO3 with siRNA. In addition, H cordata inhibited growth of human hepatocellular carcinoma xenografts in nude mice. Taken together, our results demonstrate that H cordata enhances HIF-1A/FOXO3 signaling, leading to MEF2A upregulation in HepG2 cells, and in parallel, it disturbs the expression of Bcl-2 family proteins (Bax, Bcl-2, and Bcl-xL), which results in apoptosis. Taken together, these findings demonstrate that H cordata promotes the activation of HIF-1A–FOXO3 and MEF2A pathways to induce apoptosis in human HepG2 hepatocellular carcinoma cells and is, therefore, a promising candidate for antitumor drug development.

Sign in / Sign up

Export Citation Format

Share Document